<DOC>
	<DOCNO>NCT01004432</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety switch rheumatoid arthritis ( RA ) participant inadequate response current treatment either etanercept + methotrexate adalimumab + methotrexate treatment golimumab 50 milligram ( mg ) subcutaneous ( SC ) injection ( needle insert skin back upper arm , upper thigh stomach area ) every 4 week + methotrexate . This study also design evaluate benefit safety switch participant treatment golimumab 50 mg subcutaneous injection every 4 week + methotrexate golimumab 2 milligram per kilogram ( mg/kg ) intravenous every 8 week + methotrexate , achieve mark improvement RA Week 16 .</brief_summary>
	<brief_title>Golimumab Rheumatoid Arthritis Participants With Inadequate Response Etanercept ( ENBREL ) Adalimumab ( HUMIRA )</brief_title>
	<detailed_description>The study consist main study voluntary , open-label ( participant researcher aware treatment participant receive ) , 24-week study extension . The main study include Screening Run-in Period ( Week -6 Week 0 ) , Open-label Treatment Period ( Week 0 Week 16 ) , Open-label Double-blind Treatment Period ( Week 16 Week 52 ) . The main study also include Follow-up Period Week 52 Week 64 participant participate 24-week study extension . Participants , participate 24-week extension ( Week 52 ) , receive open-label golimumab SC injection every 4 week Week 52 Week 72 followed-up Week 88 . All eligible participant initiate treatment open-label golimumab SC injection every 4 week Week 12 . At Week 16 , depend upon treatment response either participant continue receive open-label golimumab SC injection every 4 week Week 48 participant randomly assign receive follow 2 treatment : 1- golimumab 50mg SC injection every 4 week along placebo intravenous infusion every 8 week Week 48 ; 2- Placebo SC injection every 4 week along golimumab 2mg/kg intravenous infusion every 8 week Week 48 . At Week 52 , participant choose participate 24-week study extension receive open-label golimumab 50 mg SC injection every 4 week Week 72 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have inadequate RA disease control prior first administration study agent despite treatment etanercept ( Enbrel ) + methotrexate adalimumab ( Humira ) + methotrexate ( MTX ) Must receive stable dose MTX great equal ( &gt; = ) 7.5 milligram ( mg ) per week le equal ( &lt; = ) 25 mg per week least 4 consecutive week prior first screen visit must plan maintain dose throughout study Participants must receive etanercept adalimumab combination MTX minimum 3 month prior first visit Negative tuberculosis ( TB ) test Are capable provide informed consent , must obtain prior studyrelated procedure Have history latent active granulomatous infection , include TB , histoplasmosis , coccidioidomycosis , frequently contact individual carry active TB infection Have inflammatory disease RA , include limited psoriatic arthritis , ankylose spondylitis , systemic lupus erythematosus , primary Sjogren 's Lyme disease Have demonstrate discernible improvement disease activity screen prior first golimumab injection Week 0 Have know malignancy history malignancy within previous 5 year ( exception nonmelanoma skin cancer treat evidence recurrence ) Have history lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease lymphadenopathy unusual size location</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>humira , remicade</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>enbrel failure</keyword>
	<keyword>humira failure</keyword>
	<keyword>arthritis</keyword>
	<keyword>enbrel</keyword>
</DOC>